442 related articles for article (PubMed ID: 23231846)
1. The safety of methimazole and propylthiouracil in pregnancy: a systematic review.
Hackmon R; Blichowski M; Koren G
J Obstet Gynaecol Can; 2012 Nov; 34(11):1077-1086. PubMed ID: 23231846
[TBL] [Abstract][Full Text] [Related]
2. Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study.
Andersen SL; Olsen J; Wu CS; Laurberg P
J Clin Endocrinol Metab; 2013 Nov; 98(11):4373-81. PubMed ID: 24151287
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the safety between propylthiouracil and methimazole with hyperthyroidism in pregnancy: A systematic review and meta-analysis.
Liu Y; Li Q; Xu Y; Chen Y; Men Y
PLoS One; 2023; 18(5):e0286097. PubMed ID: 37205692
[TBL] [Abstract][Full Text] [Related]
4. Teratogen update: Antithyroid medications.
Romeo AN; Običan SG
Birth Defects Res; 2020 Sep; 112(15):1150-1170. PubMed ID: 32738035
[TBL] [Abstract][Full Text] [Related]
5. Antithyroid drug therapy in pregnancy and risk of congenital anomalies: Systematic review and meta-analysis.
Agrawal M; Lewis S; Premawardhana L; Dayan CM; Taylor PN; Okosieme OE
Clin Endocrinol (Oxf); 2022 Jun; 96(6):857-868. PubMed ID: 34845757
[TBL] [Abstract][Full Text] [Related]
6. Treatment of graves' disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation.
Yoshihara A; Noh J; Yamaguchi T; Ohye H; Sato S; Sekiya K; Kosuga Y; Suzuki M; Matsumoto M; Kunii Y; Watanabe N; Mukasa K; Ito K; Ito K
J Clin Endocrinol Metab; 2012 Jul; 97(7):2396-403. PubMed ID: 22547422
[TBL] [Abstract][Full Text] [Related]
7. Pregnancy outcome in women treated with methimazole or propylthiouracil during pregnancy.
Gianetti E; Russo L; Orlandi F; Chiovato L; Giusti M; Benvenga S; Moleti M; Vermiglio F; Macchia PE; Vitale M; Regalbuto C; Centanni M; Martino E; Vitti P; Tonacchera M
J Endocrinol Invest; 2015 Sep; 38(9):977-85. PubMed ID: 25840794
[TBL] [Abstract][Full Text] [Related]
8. Propylthiouracil, and methimazole, and carbimazole-related hepatotoxicity.
Akmal A; Kung J
Expert Opin Drug Saf; 2014 Oct; 13(10):1397-406. PubMed ID: 25156887
[TBL] [Abstract][Full Text] [Related]
9. Management of hyperthyroidism during pregnancy and lactation.
Azizi F; Amouzegar A
Eur J Endocrinol; 2011 Jun; 164(6):871-6. PubMed ID: 21389085
[TBL] [Abstract][Full Text] [Related]
10. Safety of antithyroid drugs in pregnancy: update and therapy implications.
Francis T; Francis N; Lazarus JH; Okosieme OE
Expert Opin Drug Saf; 2020 May; 19(5):565-576. PubMed ID: 32223355
[No Abstract] [Full Text] [Related]
11. Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: a population-based cohort study.
Wang MT; Lee WJ; Huang TY; Chu CL; Hsieh CH
Br J Clin Pharmacol; 2014 Sep; 78(3):619-29. PubMed ID: 25279406
[TBL] [Abstract][Full Text] [Related]
12. Risk of embryopathies with use of antithyroidal medications.
Andersen SL
Curr Opin Endocrinol Diabetes Obes; 2017 Oct; 24(5):364-371. PubMed ID: 28639966
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of developmental toxicity of propylthiouracil and methimazole.
Mallela MK; Strobl M; Poulsen RR; Wendler CC; Booth CJ; Rivkees SA
Birth Defects Res B Dev Reprod Toxicol; 2014 Aug; 101(4):300-7. PubMed ID: 24980470
[TBL] [Abstract][Full Text] [Related]
14. Review of antithyroid drug use during pregnancy and report of a case of aplasia cutis.
Mandel SJ; Brent GA; Larsen PR
Thyroid; 1994; 4(1):129-33. PubMed ID: 7519913
[TBL] [Abstract][Full Text] [Related]
15. A Disproportionality Analysis of the Adverse Effect Profiles of Methimazole and Propylthiouracil in Patients with Hyperthyroidism Using the Japanese Adverse Drug Event Report Database.
Arai M; Tsuno T; Konishi H; Nishiyama K; Terauchi Y; Inoue R; Shirakawa J
Thyroid; 2023 Jul; 33(7):804-816. PubMed ID: 37130038
[No Abstract] [Full Text] [Related]
16. Analysis of 90 cases of antithyroid drug-induced severe hepatotoxicity over 13 years in China.
Yang J; Li LF; Xu Q; Zhang J; Weng WW; Zhu YJ; Dong MJ
Thyroid; 2015 Mar; 25(3):278-83. PubMed ID: 25384184
[TBL] [Abstract][Full Text] [Related]
17. The efficiency and safety of methimazole and propylthiouracil in hyperthyroidism: A meta-analysis of randomized controlled trials.
Tan S; Chen L; Jin L; Fu X
Medicine (Baltimore); 2021 Jul; 100(30):e26707. PubMed ID: 34397700
[TBL] [Abstract][Full Text] [Related]
18. Aplasia cutis congenita in surviving co-twin after propylthiouracil exposure in utero.
Löllgen RM; Calza AM; Schwitzgebel VM; Pfister RE
J Pediatr Endocrinol Metab; 2011; 24(3-4):215-8. PubMed ID: 21648296
[TBL] [Abstract][Full Text] [Related]
19. The onset of antineutrophil cytoplasmic antibody-associated vasculitis immediately after methimazole was switched to propylthiouracil in a woman with Graves' disease who wished to become pregnant.
Kimura M; Seki T; Ozawa H; Ishihara T; Komatsu M; Tajiri S; Yanagi H; Nishina M; Noh JY; Fukagawa M; Takagi A
Endocr J; 2013; 60(3):383-8. PubMed ID: 23154533
[TBL] [Abstract][Full Text] [Related]
20. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease.
Nakamura H; Noh JY; Itoh K; Fukata S; Miyauchi A; Hamada N
J Clin Endocrinol Metab; 2007 Jun; 92(6):2157-62. PubMed ID: 17389704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
